top of page
  • Writer's pictureMichael Zürcher

Swiss Pharmaceutical Market 2023: Further Growth Achieved

In 2023, the Swiss pharmaceutical market showcased significant resilience and innovation, reflecting its pivotal role in the global healthcare landscape. Despite regulatory price adjustments, the market not only sustained growth but also continued to drive advancements in critical areas of healthcare. Below is a detailed examination of the sector’s performance, including growth rates in innovative sectors and the strategic implications for pharmaceutical companies.


Market Dynamics and Growth

The market experienced a 4.9% increase in sales, reaching 7.4 billion Swiss francs. This growth was curbed to the tune of 2.7%, however, due to regulatory price reductions. Noteworthy is the market’s adaptability and its sustained focus on innovation despite these price adjustments.

Innovative Medicines

Innovative treatments in oncology, autoimmune diseases and antiviral medications were particularly notable for their contribution to market growth, with respective growth rates of 6.8%, 6.3% and 1.6%. These segments underscore the Swiss market’s commitment to addressing critical healthcare challenges through advanced research and development. The impact of these innovations is significant, offering new hope and improved quality of life for patients while potentially reducing the long-term costs of healthcare through more effective disease management and treatment outcomes.


Generics and Biosimilars

The generics segment saw a 4.4% increase in sales, reaching 937.8 million Swiss francs and achieving a record market share of 64%. Biosimilars also demonstrated substantial growth, with a 25.8% increase in sales to 174.1 million Swiss francs, driven by the expiration of patents for several biologic drugs.



The Swiss pharmaceutical market’s performance in 2023 reflects a robust and forward-looking industry that is characterized by commitment to innovation, strategic market positioning and responsiveness to regulatory and economic pressures. For pharmaceutical companies, these trends represent significant opportunities for growth and contribution to global healthcare advancements.


Are you considering the Swiss market for your pharmaceutical expansion? Reach out to us for expert guidance and explore the many opportunities that Switzerland has to offer your business.





bottom of page